NASDAQ: VYNE
VYNE Therapeutics Inc.CIK 0001566044 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (WOLF 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade VYNE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(U.S. dollars and share data in thousands, except per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | ||||
| Royalty revenues | 97 | 69 | 183 | 271 |
| Total revenues | 97 | 69 | 183 | 271 |
| Operating expenses: | ||||
| Research and development | 788 | 4,881 | 1,605 | 11,004 |
| General and administrative | 2,411 | 2,730 | 5,496 | 6,005 |
| Total operating expenses | 3,199 | 7,611 | 7,101 | 17,009 |
| Operating loss | (3,102) | (7,542) | (6,918) | (16,738) |
| Other income, net | 203 | 1,795 | 434 | 2,388 |
| Loss from continuing operations before income taxes | (2,899) | (5,747) | (6,484) | (14,350) |
| Income tax expense | — | — | — | — |
| Loss from continuing operations | (2,899) | (5,747) | (6,484) | (14,350) |
| Loss from discontinued operations, net of income taxes | (108) | (8) | (108) | (16) |
| Net loss | (3,007) | (5,755) | (6,592) | (14,366) |
| Loss per share from continuing operations, basic and diluted | (3.38) | (6.72) | (7.56) | (16.80) |
| Loss per share from discontinued operations, basic and diluted | (0.13) | (0.01) | (0.12) | (0.02) |
| Loss per share, basic and diluted | (3.51) | (6.73) | (7.68) | (16.82) |
| Weighted average shares outstanding basic and diluted | 858 | 855 | 858 | 854 |
| Other comprehensive loss: | ||||
| Unrealized losses on marketable securities, net of tax of $0 | — | (2) | (2) | (22) |
| Total other comprehensive loss | — | (2) | (2) | (22) |
| Comprehensive loss | (3,007) | (5,757) | (6,594) | (14,388) |
Condensed Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands, except share and per share data)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | 22,925 | 24,027 |
| Investment in marketable securities | — | 4,981 |
| Prepaid and other current assets | 601 | 1,002 |
| Total Current Assets | 23,526 | 30,010 |
| Non-Current Assets: | ||
| Property and equipment, net | 78 | 90 |
| Non-current prepaid expenses and other assets | — | 60 |
| Total Non-Current Assets | 78 | 150 |
| Total Assets | 23,604 | 30,160 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities: | ||
| Trade payables | 614 | 1,041 |
| Accrued expenses | 815 | 941 |
| Employee-related obligations | 113 | 413 |
| Total Current Liabilities | 1,542 | 2,395 |
| Total Liabilities | 1,542 | 2,395 |
| Commitments and Contingencies | ||
| Stockholders' Equity: | ||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025; and 668,327 and 666,463 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 786,307 | 785,416 |
| Accumulated other comprehensive income | — | 2 |
| Accumulated deficit | (764,245) | (757,653) |
| Total Stockholders' Equity | 22,062 | 27,765 |
| Total Liabilities and Stockholders’ Equity | 23,604 | 30,160 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(U.S. dollars in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash Flows From Operating Activities: | ||
| Net loss | (6,592) | (14,366) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 12 | 12 |
| Stock-based compensation | 910 | 1,292 |
| Amortization of premium or discount on marketable securities | (21) | (538) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets and operating lease right-of-use assets | 462 | 306 |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | (844) | (8,896) |
| Operating lease liabilities | — | (74) |
| Net cash used in operating activities | (6,073) | (22,264) |
| Cash Flows From Investing Activities: | ||
| Proceeds from sale and maturity of marketable securities | 5,000 | 47,850 |
| Purchases of marketable securities | — | (23,344) |
| Net cash provided by investing activities | 5,000 | 24,506 |
| Cash Flows From Financing Activities: | ||
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | (29) | (121) |
| Net cash used in financing activities | (29) | (121) |
| (Decrease) increase in cash and cash equivalents | (1,102) | 2,121 |
| Cash and cash equivalents at beginning of the period | 24,027 | 19,926 |
| Cash and cash equivalents at end of the period | 22,925 | 22,047 |
| Supplementary information on investing and financing activities not involving cash flows: | ||
| Issuance of vested shares under employee stock purchase plan | 10 | 13 |
| Cashless exercise of pre-funded warrants | — | 1 |
Amounts as printed on the EDGAR/iXBRL face — (U.S. dollars and share data in thousands, except per share data); (U.S. dollars in thousands, except share and per share data); (U.S. dollars in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗